Format

Send to

Choose Destination
Cancer Metab. 2015 Mar 25;3:3. doi: 10.1186/s40170-015-0129-1. eCollection 2015.

Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature.

Author information

1
Department of Internal Medicine, Michigan State University, East Lansing, MI 48824 USA.
2
Department of Pathology, Sparrow Hospital, Lansing, MI 48912 USA ; Department of Neurology and Ophthalmology, Michigan State University, East Lansing, MI 48824 USA.
3
Department of Clinical Nutrition Services, Sparrow Hospital Lansing Mi, Michigan State University, East Lansing, MI 48824 USA.
4
Department of Radiology, College of Human Medicine, Michigan State University, East Lansing, MI 48824 USA.
5
Department of Physiology, College of Natural Science, Michigan State University, East Lansing, MI 48824 USA.
6
School of Biological and Population Health Sciences, College of Public Health and Human Sciences, Oregon State University, Corvallis, OR USA.
7
Department of Family Medicine, Michigan State University, East Lansing, MI 48824 USA.

Abstract

BACKGROUND:

Based on the hypothesis that cancer cells may not be able to metabolize ketones as efficiently as normal brain cells, the ketogenic diet (KD) has been proposed as a complementary or alternative therapy for treatment of malignant gliomas.

CASE PRESENTATION:

We report here our experience in treating two glioma patients with an IRB-approved energy-restricted ketogenic diet (ERKD) protocol as monotherapy and review the literature on KD therapy for human glioma patients. An ERKD protocol was used in this pilot clinical study. In addition to the two patients who enrolled in this study, we also reviewed findings from 30 other patients, including 5 patients from case reports, 19 patients from a clinical trial reported by Rieger and 6 patients described by Champ. A total of 32 glioma patients have been treated using several different KD protocols as adjunctive/complementary therapy. The two patients who enrolled in our ERKD pilot study were monitored with twice daily measurements of blood glucose and ketones and daily weights. However, both patients showed tumor progression while on the ERKD therapy. Immunohistochemistry reactions showed that their tumors had tissue expression of at least one of the two critical mitochondrial ketolytic enzymes (succinyl CoA: 3-oxoacid CoA transferase, beta-3-hydroxybutyrate dehydrogenase 1). The other 30 glioma patients in the literature were treated with several different KD protocols with varying responses. Prolonged remissions ranging from more than 5 years to 4 months were reported in the case reports. Only one of these patients was treated using KD as monotherapy. The best responses reported in the more recent patient series were stable disease for approximately 6 weeks. No major side effects due to KD have been reported in any of these patients.

CONCLUSIONS:

We conclude that 1. KD is safe and without major side effects; 2. ketosis can be induced using customary foods; 3. treatment with KD may be effective in controlling the progression of some gliomas; and 4. further studies are needed to determine factors that influence the effectiveness of KD, whether as a monotherapy, or as adjunctive or supplemental therapy in treating glioma patients.

TRIAL REGISTRATION:

ClinicalTrials.gov# NCT01535911.

KEYWORDS:

Humans; Ketogenic diet; Primary brain neoplasm; Treatment

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center